Big Pharma Companies Acquire Two SoCal Biotech Startups

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Big Pharma Companies Acquire Two SoCal Biotech Startups
Photo by Sam Moqadam on Unsplash

Two Southern California biotech startups got swallowed up this week as big pharma benefitted from the record-breaking year of investment in the industry.


Pharmaceutical giant Eli Lilly plucked up a Pasadena startup Protomer Technologies for $1 billion. The company is working on "smart insulin" to treat diabetes.

Another SoCal startup, El Segundo-based Integrity Bio, was acquired by New York drug development company Curia, formerly known as AMRI. Terms of both deals weren't disclosed.

Biotech has been on a tear. Protomer, which last year received an undisclosed funding amount, is one of over a thousand companies who benefited from a banner year in biotech. According to Pitchbook, the industry saw a 60% year-over-year increase in venture capital deal activity in 2020 the largest year-over-year increase ever seen.

Those deals are coming to fruition now, as Protomer and Camarillo-based Integrity Bio, a formulation pharmaceutical upstart, are shedding the need for funding as they get acquired by pharmaceutical companies.

"If Big Pharma wants to start buying assets, more venture capital is going to start pouring into biotech because they know that Big Pharma will be interested in acquiring it down the road," said Bill Bolding, a senior analyst at Provident Healthcare Partners.

Eli Lilly's acquisition of Protomer will give it an even stronger hold on diabetes treatment. Eli Lily's most recent diabetes drug, tirzepatide, outperformed one of its market rivals, and the company is pursuing FDA approval. But glucose-sensing insulin is the next frontier of diabetes treatments, as it has the ability to take into account peoples' unique blood sugar levels.

"With insulin, it's a very complicated drug to use," said Ruth Gimeno, Eli Lilly's vice president of diabetes research. "It's a very efficacious drug, but current insulins are not as safe as we would like them to be. So glucose sensing insulin would just be a complete game changer here."

Curia, a company that formulates and manufactures drugs for other companies, will use Integrity Bio to establish a West Coast presence in the U.S. and get access to the former upstart's slew of clients ranging from startups to Fortune 500 companies. The acquisition is expected to close in the third quarter of 2021.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

Office Hours: Former Lawyer Turned CEO Diankha Linear on Cultivating Community

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Diankha Linear
Diankha Linear

On this episode of Office Hours, Community CEO Diankha Linear joins host Spencer Rascoff to discuss her foray into the startup world and the strategic approaching to scaling up.

Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

LA Tech ‘Moves’: Dreamscape, LinQuest and PetDX Gain New CEOs

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

LA Tech ‘Moves’: Dreamscape, LinQuest and PetDX Gain New CEOs

“Moves,” our roundup of job changes in L.A. tech, is presented by Interchange.LA, dot.LA's recruiting and career platform connecting Southern California's most exciting companies with top tech talent. Create a free Interchange.LA profile here—and if you're looking for ways to supercharge your recruiting efforts, find out more about Interchange.LA's white-glove recruiting service by emailing Sharmineh O’Farrill Lewis (sharmineh@dot.la). Please send job changes and personnel moves to moves@dot.la.

***

Read moreShow less

This Week in ‘Raises’: ADARx Pharmaceuticals Lands $46M, PLAI Labs Scores $32M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

This Week in ‘Raises’: ADARx Pharmaceuticals Lands $46M, PLAI Labs Scores $32M
This Week in ‘Raises’: ContractSafe Inks $27.5M, Deal Box Collects $125M

A local RNA base-editing platform raised fresh funding to advance its drug development pipeline, while a local Web3 company founded by former MySpace and Jam City founders Chris DeWolfe and Aber Whitcomb scored funding to build out an artificial intelligence backed by generative AI that allows users to create and upload their own digital assets to the game.

***

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending